R&D Excellence

Business Issues
Solutions
Insights

While life sciences innovation has delivered significant improvement in patient outcomes, the costs and time to develop new products continues to rise while the commercial success of these products has become more elusive. R&D organizations need to become more cost effective in how they develop new products while also increasing the value of these products through stronger evidence, especially in the real world.

New (Real World) Evidence is Required

The evidence now required to support a pharmaceutical brand is becoming far more complex. Because pharmaceutical companies need to further prove to payers, physicians, and patients the value of their therapies, they need to create a more comprehensive strategy for developing evidence throughout the lifecycle of the brand, not just during clinical trials, but in the real world as well.

Clinical Trials are Expensive

About 80% of clinical trials either fail to meet or miss their milestones, while the complexity of trials continues to increase. The net result is an ever-increasing cost of development, with an average of $2-plus billion spent on the development cost of each asset. Trying to ensure that trials are operational and efficient in execution is essential to controlling costs, while also making sure new therapies are commercialized sooner.

Investment in New Technology and Analytics is Unrealized

While companies are investing in technology and analytics, these investments haven’t always produced the results expected – requiring pharmaceutical companies to look for new ways to improve the impact of this technology and new data in driving efficiency and value.

Fulfilling the Promise of Real-World Evidence

> READ ARTICLE

Four Pillars to Achieve Patient Centricity

> READ ARTICLE

Bringing business impact to the science of R&D

Lifecycle Evidence Strategy

Based on a deep understanding of payers, physicians, and patients, ZS helps clients generate the evidence required to articulate and support product value to various stakeholders. This includes the design of clinical trials, but also generating real-world evidence continuously throughout its lifecycle to demonstrate the effectiveness and value of the drug.

Clinical Trial Analytics

ZS brings cross-functional stakeholders together to focus on analytics which will reduce costs, risks and time associated with clinical trial design, planning and execution. ZS helps clients optimize the feasibility of trials, assess site readiness, predict key drivers of site success, forecast patient enrollment and improve the likelihood that the trial will deliver the required evidence at the lowest cost.

Medical Affairs

ZS draws on proven methodologies, frameworks and deep analytics to design strategies and processes to improve resource planning, tackle tough departmental issues, and introduce new feedback mechanisms and KPIs that drive growth in the medical affairs space. In addition to assessing the internal needs across stakeholders within medical affairs, commercial, development, compliance and HR departments, ZS also leverages voice of the customer market research to gather feedback from customers about their own needs and MSLs’ effectiveness.

Clinical & Real-World Data Science

ZS helps companies use real-world data in a way that’s meaningful, scalable and actionable. By bringing together structured and unstructured data from across both primary sources (e.g., case report forms, electronic medical and health records, observational studies, patient registries and health surveys) and secondary sources (e.g., clinical chart reviews, registries, insurance claims databases, etc.), ZS can easily integrate and analyze the information to generate meaningful insights that improve the design and execution of studies and prove the value of their therapies.

R&D Intelligence Platforms

ZS eliminates the need for organizations to build the infrastructure to collect, standardize, analyze and visualize data. Bringing together technology and analytic capabilities, ZS helps to maximize the value of the real world evidence and optimize the execution of clinical trials – allowing you to increase business impact at a lower investment cost.

Fulfilling the Promise of Real-World Evidence

> READ ARTICLE

Four Pillars to Achieve Patient Centricity

> READ ARTICLE

Patient Centricity Insights

	Video: What Data Sources Can Help to Transform Patient Recruitment and Engagement? Watch this video to learn which data sources can help improve overall engagement with patients.
	E-book: Inviting Patients to the Center of Drug Development Learn how life sciences companies can embrace patient centricity and start reaping its benefits with ZS’s four-pillar patient centricity framework.
	ACT Article: Four Pillars to Achieve Patient Centricity Read our byline article in ACT to learn four pillars of patient centricity that help life sciences companies adapt to ever-evolving patient needs and to improve clinical trial outcomes.
	Video: Why Do Patient-Centric Companies Need to Go Beyond Rational Thinking? Watch this video to find out why it’s vital for life sciences companies to go beyond rational thinking to better understand patients and improve outcomes.
	Blog: How to Develop a Patient-Centric R&D Process Learn the steps life sciences can take to start their journey towards patient centricity.
	Video: What Are the Four Pillars of Patient Centricity? Watch this video to learn about our four-pillar framework for embracing patient centricity.
	Blog: How Biopharma Companies Are Working to Uncover and Meet Patient Needs Learn how life sciences companies can collaborate with patients to uncover their needs.
	Video: What Does It Take for Life Sciences Companies to Succeed With Patient Recruitment? Watch this video to find out how to go beyond the latest solutions and techniques to improve patient recruitment in clinical trials.
	Article: Pick Up the Pace on Patient Centricity Read this article to learn how a patient-centered approach can alter clinical trials and the four pillars you need to incorporate today.
	Video: What Does It Take for Life Sciences Teams to be More Patient-Centric? Watch this video to get expert tips on how life sciences companies can become more patient-centric.
	Blog: How Technology and Analytics Are Helping Big Pharma Improve Patient Engagement in R&D Learn how progressive life sciences companies are leveraging technology to connect with patients in new ways.
	Video: What Is Patient Centricity, and Why Is It Important for Life Sciences? Patient centricity isn’t just a buzzword. Watch this video to learn about how being patient-centric can benefit your company.
	Blog: How Pharma Companies Are Engaging Patients as R&D Partners Discover how progressive life sciences companies have involved patients beyond trials.
	Video: Four Pillars to Achieve Patient Centricity Watch this video to learn the challenges life sciences companies encounter while taking steps towards patient centricity and a four- pillar strategy to accomplish patient centricity.

Real World Evidence Insights

	Video: What should companies know before investing in real-world data sources? ZS’s Qin Ye discusses key questions that life sciences companies need to consider before investing in real-world data.
	Video: How will real-world evidence change the healthcare landscape in the next few years? Qin Ye, ZS’s global head of RWE, describes what the future may hold for real-world evidence.
	Video: What skill sets are necessary for an effective real-world evidence team? ZS’s Qin Ye discusses the different skill sets that life sciences companies should invest in to create a strong real-world-evidence capability.
	Video: How can companies find data sets that suit their needs? RWE experts Qin Ye and Abhay Jha discuss the factors that life sciences companies should keep in mind before investing in data.
	Video: What is a federated model, and why use one? In this video, ZS’s Abhay Jha discusses how a federated real-world-data model can encourage innovation while keeping the data centralized.
	Video: What role does technology play in making the real-world evidence capability effective? In this video, Abhay Jha describes the role that technology plays in making a real-world-evidence capability more effective.
	Video: Which team stands to benefit the most by leveraging real-world data? ZS’s Abhay Jha talks about how real-world data will benefit all functional groups at life sciences companies.
	Video: Are data partnerships necessary to establish a real-world evidence capability? ZS’s Abhay Jha explains how data partnerships play an important role in launching a strong real-world-evidence capability.
	Blog: Ramping Up Real-World Evidence: Assessing the FDA’s New RWE Framework With the unveiling of its real-world evidence framework, the FDA is considering the use of RWE a top strategic priority. Here’s what pharma companies need to know.
	Article: Securing a Winning Strategy for Real-World Evidence In the latest issue of PharmaExec, ZS’s real-world-evidence lead, Qin Ye, and other industry experts share their thoughts on how life sciences companies can improve their RWE strategies.
	Article: What Can Pharma Expect in 2019? What does 2019 hold for life sciences? ZS’s Aaron Mitchell and other industry experts share their predictions in this eyeforpharma article.
	Article: Can payers trust our data? Real-world data is playing an increasingly important role in improving patient health, but is there a lack of trust between payers and pharma companies? ZS’s Aaron Mitchell weighs in on closing the trust gap.
	Blog: How the Right RWE Platform Serves Up the Ingredients for Innovation Here’s why the right RWE technology platform—like a well-stocked kitchen—provides a pharma organization with the proper ingredients to innovate.
	Article: Fulfilling the Promise of Real World Evidence Establishing a RWE capability across a global life sciences company requires much more than just technology. Learn the five key steps for establishing a successful RWE capability.
	Video: Driving Patient Care With Real-World Evidence Watch this video to learn about the role of RWE in life sciences and some best practices for developing an RWE strategy.
	Blog: Collaboration in Clinical Operations: Three Takeaways From SCOPE 2018 The role of clinical operations in life sciences has evolved, but what’s ahead? ZS experts share their key takeaways from SCOPE 2018.
	Blog: Three Emerging Themes From SCOPE 2017 As the abundance of patient data continues to grow, the healthcare industry is continuing to find innovative ways to employ it. ZS experts share their key takeaways from SCOPE 2017.

Clinical Trial Insights

	Article: How Pharma Can Work With the FDA to Embrace Innovation and Overcome Its ‘Adoptaphobia’ Pharma companies need to get over their “adoptaphobia” and embrace innovation in clinical research. Here’s how.
	Blog: Advancements in Data Science and Big Data Technologies Will Change the Way Clinical Decisions Are Made Today Advances in data science can be used to improve clinical trial site selection and recruitment, enable advanced analytics and design and execute better trials. 4 key takeaways from SCOPE 2019.
	Whitepaper: How Your Clinical Trial Can Succeed in a Crowded Market How can life sciences companies improve patient enrolment in clinical trials? ZS experts share 4 key strategies.
	Article: Is Data Science the Treatment for Inefficiencies in Clinical Trial Operations? Here’s how data science can transform the way that life sciences companies find the right patient population.
	Article: How Data and Analytics Can Improve Clinical Trial Feasibility Learn from ZS experts how to improve the feasibility of clinical trials using seven key building blocks for success.